Synonyms: 9F3v13 | RhuMAB IFNalpha | rhuMAb interferon-α
Compound class:
Antibody
Comment: Rontalizumab is a humanized monoclonal antibody targeting interferon alpha (IFNα) that has immunomodulatory potential. It was humanized from a mouse monoclonal as described in [2], and peptide sequences of the antibody (identified as humanized 9F3v13) are claimed in Genentech patent US7582445 [1].
Rontalizumab is functionally similar to sifalimumab. Development of both of these anti-IFNα agents has been discontinued. Compare these with anifrolumab, which targets the type I interferon receptor (IFNAR1) rather than the ligand itself, and which has progressed to Phase 3 clinical trial. A 3D X-ray structure of rontalizumab's Fab domain bound to IFNα2 has been published (PDB identifier 4Z5R) [5]. |
Classification | |
Compound class | Antibody |
International Nonproprietary Names | |
INN number | INN |
9114 | rontalizumab |
Synonyms |
9F3v13 | RhuMAB IFNalpha | rhuMAb interferon-α |
Database Links | |
Specialist databases | |
IMGT/mAb-DB | 327 |
Other databases | |
GtoPdb PubChem SID | 340590270 |
Search PubMed clinical trials | rontalizumab |
Search PubMed titles | rontalizumab |
Search PubMed titles/abstracts | rontalizumab |